Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to $56590.0.

  • BioCorRx's Current Deferred Revenue changed N/A to $56590.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $56590.0, marking a year-over-year change of. This contributed to the annual value of $56590.0 for FY2024, which is 129901.11% up from last year.
  • BioCorRx's Current Deferred Revenue amounted to $56590.0 in Q3 2025.
  • In the past 5 years, BioCorRx's Current Deferred Revenue registered a high of $98637.0 during Q1 2021, and its lowest value of $4045.0 during Q4 2023.
  • Moreover, its 5-year median value for Current Deferred Revenue was $50526.5 (2022), whereas its average is $46297.5.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 8915.58% in 2023, then surged by 129901.11% in 2024.
  • Over the past 5 years, BioCorRx's Current Deferred Revenue (Quarter) stood at $72282.0 in 2021, then tumbled by 48.4% to $37301.0 in 2022, then crashed by 89.16% to $4045.0 in 2023, then soared by 1299.01% to $56590.0 in 2024, then changed by 0.0% to $56590.0 in 2025.
  • Its Current Deferred Revenue stands at $56590.0 for Q3 2025, versus $56590.0 for Q2 2025 and $56590.0 for Q4 2024.